A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multipl...

PrintE-mail
Title A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma
Contact CB
Principal Investigator Hong Liu MD
Study Number 221012
Phase3
Summary This is a phase 3, randomized, double-blind, multicenter study to evaluate the safety and efficacy of MLN9708 versus placebo in patients iwth relapsed and/or refractory multiple myeloma (MM) who are treated with lenalidomide and dexamethasone as their standard therapy.
Eligibility See Clinicaltrials.gov listing for current eligibility criteria.
For more information about the clinical study go to Clinicaltrial.Gov